These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 33668008)

  • 21. Design, synthesis and biological evaluation of di-substituted cinnamic hydroxamic acids bearing urea/thiourea unit as potent histone deacetylase inhibitors.
    Ning C; Bi Y; He Y; Huang W; Liu L; Li Y; Zhang S; Liu X; Yu N
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6432-5. PubMed ID: 24119555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quinazoline-based hydroxamic acid derivatives as dual histone methylation and deacetylation inhibitors for potential anticancer agents.
    Zheng H; Dai Q; Yuan Z; Fan T; Zhang C; Liu Z; Chu B; Sun Q; Chen Y; Jiang Y
    Bioorg Med Chem; 2022 Jan; 53():116524. PubMed ID: 34847495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
    Ojha R; Huang HL; HuangFu WC; Wu YW; Nepali K; Lai MJ; Su CJ; Sung TY; Chen YL; Pan SL; Liou JP
    Eur J Med Chem; 2018 Apr; 150():667-677. PubMed ID: 29567459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells.
    Valente S; Trisciuoglio D; Tardugno M; Benedetti R; Labella D; Secci D; Mercurio C; Boggio R; Tomassi S; Di Maro S; Novellino E; Altucci L; Del Bufalo D; Mai A; Cosconati S
    ChemMedChem; 2013 May; 8(5):800-11. PubMed ID: 23526814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
    Shultz M; Fan J; Chen C; Cho YS; Davis N; Bickford S; Buteau K; Cao X; Holmqvist M; Hsu M; Jiang L; Liu G; Lu Q; Patel C; Suresh JR; Selvaraj M; Urban L; Wang P; Yan-Neale Y; Whitehead L; Zhang H; Zhou L; Atadja P
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4909-12. PubMed ID: 21742496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis and biological evaluation of coumarin-based N-hydroxycinnamamide derivatives as novel histone deacetylase inhibitors with anticancer activities.
    Ding J; Liu J; Zhang Z; Guo J; Cheng M; Wan Y; Wang R; Fang Y; Guan Z; Jin Y; Xie SS
    Bioorg Chem; 2020 Aug; 101():104023. PubMed ID: 32650178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
    Liu J; Zhou J; He F; Gao L; Wen Y; Gao L; Wang P; Kang D; Hu L
    Eur J Med Chem; 2020 Apr; 192():112189. PubMed ID: 32151834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
    Luo G; Lin X; Ren S; Wu S; Wang X; Ma L; Xiang H
    Eur J Med Chem; 2021 Dec; 226():113870. PubMed ID: 34610548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
    Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
    Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity.
    Gaisina IN; Tueckmantel W; Ugolkov A; Shen S; Hoffen J; Dubrovskyi O; Mazar A; Schoon RA; Billadeau D; Kozikowski AP
    ChemMedChem; 2016 Jan; 11(1):81-92. PubMed ID: 26592932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.
    Chetan B; Bunha M; Jagrat M; Sinha BN; Saiko P; Graser G; Szekeres T; Raman G; Rajendran P; Moorthy D; Basu A; Jayaprakash V
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3906-10. PubMed ID: 20605448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
    Li X; Hou J; Li X; Jiang Y; Liu X; Mu W; Jin Y; Zhang Y; Xu W
    Eur J Med Chem; 2015 Jan; 89():628-37. PubMed ID: 25462271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biological evaluation of 4,5-diarylimidazoles with hydroxamic acid appendages as novel dual mode anticancer agents.
    Mahal K; Schruefer S; Steinemann G; Rausch F; Schobert R; Biersack B; Höpfner M
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):691-700. PubMed ID: 25618416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines.
    Sixto-López Y; Gómez-Vidal JA; de Pedro N; Bello M; Rosales-Hernández MC; Correa-Basurto J
    Sci Rep; 2020 Jun; 10(1):10462. PubMed ID: 32591593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
    Liao V; Liu T; Codd R
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6200-4. PubMed ID: 22932316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
    Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
    Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors.
    Routholla G; Pulya S; Patel T; Abdul Amin S; Adhikari N; Biswas S; Jha T; Ghosh B
    Bioorg Chem; 2021 Sep; 114():105050. PubMed ID: 34120025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.
    He R; Chen Y; Chen Y; Ougolkov AV; Zhang JS; Savoy DN; Billadeau DD; Kozikowski AP
    J Med Chem; 2010 Feb; 53(3):1347-56. PubMed ID: 20055418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
    Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
    Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of N-hydroxycinnamamide-based HDAC inhibitors with improved HDAC inhibitory activity and in vitro antitumor activity.
    Zang J; Shi B; Liang X; Gao Q; Xu W; Zhang Y
    Bioorg Med Chem; 2017 May; 25(9):2666-2675. PubMed ID: 28336407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.